摘要 |
Use of a ERRy agonist or pharmaceutically acceptable salt thereof, for the prevention, delay of progression or the treatment of diabetes, insulin resistance, metabolic disease/metabolic syndrome, dyslipidemia, obesity, overweight, Neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, Huntington's disease or improvement of exercise endurance capacity. |
申请人 |
NOVARTIS AG;NOVARTIS PHARMA GMBH;RANGWALA, SHAMINA M.;STEVENSON, SUSAN C.;WU, ZHIDAN |
发明人 |
RANGWALA, SHAMINA M.;STEVENSON, SUSAN C.;WU, ZHIDAN |